Keywords: genta, starts, phi/iia, g3139, study, inc, start
Genta Starts PhI/IIA G3139 Study
Article | 25 June 1998
Genta Inc is to start a Phase I/IIa study of its bcl-2 antisensedrug, code-named G3139, in combination with dacarbazine ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
